在氨酸激活抗血素的Allosteric通信网络由肝素
1Insight-DNA, Oak Park, IL 60302, USA.
International journal of molecular sciences
|September 27, 2025
概括
抗血素 (AT) 激活涉及由保存网络稳定的一种形状变化. 这个网络充当了分子锁,它的破坏增强了AT的反应性,为新的变体提供了洞察力.
科学领域:
- 生物化学 生物化学
- 结构生物学 结构生物学
- 分子生物学分子生物学
背景情况:
- 抗血素 (AT) 通过抑制血素和FXa等蛋白酶来调节凝血.
- AT激活涉及从压抑 (R) 到激活 (AH) 状态的构造过渡,受氨酸结合的影响.
- 了解AT激活的结构动态对于开发抗凝剂和治疗策略至关重要.
研究的目的:
- 识别和描述负责稳定抗血抑制状态的全性通信网络 (ACN).
- 阐明肝素结合触发AT激活的机制.
- 探索工程 AT 变体的工程潜力,这些变体不依赖肝素.
主要方法:
- 计算结构分析以识别全性通信网络 (ACN).
- 主要残留物在ACN和其他监管区域的局部定向突变发生.
- 模拟分子动力学以评估突变对蛋白质灵活性和动力学的影响.
- 生物化学试验用于测量抗血素反应性和热稳定性.
主要成果:
- 包括H120,Y131和Y166残留物在内的进化保守的全沟通网络 (ACN) 被确定为稳定AT抑制状态的关键.
- ACN残留物的突变性增强了AT对FXa的本源反应性,并降低了热稳定性,证实了它们在维持抑制状态方面的作用.
- 氨酸结合被证明可以解开ACN的"分子锁",从氨酸结合部位 (HBS) 到反应中心循环 (RCL) 启动一连串的结构变化.
- 分析显示了微妙的能量平衡,涉及S380插入和调节激活值的E381-R197盐桥.
- 对ACN突变的分子动力学模拟表明,HBS和RCL领域的灵活性增加,支持协同的全结合.
结论:
- 该ACN作为一个分子锁,抑制构造能量和防止过早的AT激活.
- 肝素结合释放了这种约束,引发了一连串导致AT激活的事件.
- 这些发现为AT全调节提供了新的机制性见解,并建议设计具有改变肝素依赖性的修饰AT变体的策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.7K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.7K
Extrinsic and Intrinsic Pathways of Hemostasis
12.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
12.1K
Allosteric Regulation
63.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
63.0K
Intracellular Signaling Affects Focal Adhesions
3.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.5K
Coagulation
9.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K


